Immunogenicity of Haemophilus influenzae Type b Conjugate Vaccines in Korean Infants: A Meta-analysis.
10.3346/jkms.2010.25.1.90
- Author:
Hyunju LEE
1
;
Seokyung HAHN
;
Hoan Jong LEE
;
Kyung Hyo KIM
Author Information
1. Department of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Korea. kaykim@ewha.ac.kr
- Publication Type:Original Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't
- Keywords:
Haemophilus influenza type b;
Vaccines;
Immunity;
Meta-analysis
- MeSH:
Antibodies/analysis;
Bacterial Capsules/*immunology/metabolism;
Haemophilus Vaccines/*immunology/metabolism;
Humans;
Infant;
Republic of Korea;
Tetanus Toxoid/chemistry/metabolism;
Vaccines, Conjugate/immunology/metabolism
- From:Journal of Korean Medical Science
2010;25(1):90-96
- CountryRepublic of Korea
- Language:English
-
Abstract:
A meta-analysis was performed on the immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines after 2 (2 and 4 months) and 3 doses (2, 4, and 6 months) in Korean infants. A database search of MEDLINE, KoreaMed, and Korean Medical Database was done. The primary outcome measure was the proportion of infants with anti-polyribosylribitol phosphate (PRP) concentrations > or =1.0 microgram/mL. Eight studies including eleven trials were retrieved. One trial reported on the diphtheria toxoid conjugate vaccine (PRP-D) and 2 trials each on the mutant diphtheria toxin (PRP-CRM) and Neisseria meningitidis outer-membrane protein (PRP-OMP) conjugate vaccine. Heterogeneity in study designs between trials on PRP-CRM was noted and one trial reported on a monovalent and another on a combination PRP-OMP vaccine. Thus, a meta-analysis was conducted only on the tetanus toxoid conjugate vaccine (PRP-T). After a primary series of 2 doses and 3 doses, 80.6% (95% confidence interval [CI]; 76.0-85.1%) and 95.7% (95% CI; 94.0-98.0%) of infants achieved an antibody level > or =1.0 microgram/mL, respectively. The immunogenic response to the PRP-T vaccine was acceptable after a primary series of 3 doses and also 2 doses. A reduced number of doses as a primary series could be carefully considered in Korean infants.
